P ancreatic cancer is a top cause of cancer-related mortality worldwide and is the third leading cause in the United States. 1 This high mortality rate is largely related to the diagnosis of patients at advanced stages when the disease is unresectable and thus incurable. 2 Despite the development of new combination chemotherapy programs, 3, 4 most patients with advanced pancreatic cancer survive for fewer than 12 months. 1 Therefore, identifying new therapies that can improve survival among patients with pancreatic cancer is urgently needed.
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors primarily used for their lipidlowering properties, and the prevention and treatment of cardiovascular disease. More recently, this class of medication has been studied for chemopreventative and chemotherapeutic properties given their complex effects on inflammation, angiogenesis, and cellular proliferation and apoptosis. [5] [6] [7] [8] Although a meta-analysis of 27 randomized controlled trials failed to show an effect of statin use on overall cancer incidence or mortality, 9 observational studies support that statins may decrease the risk of certain cancer types as well as cancer-related mortality. 7, 8, 10, 11 Among patients with pancreatic cancer, retrospective cohort studies have suggested a survival benefit associated with regular statin use both in resectable and unresectable pancreatic cancer [12] [13] [14] [15] [16] ; however, these prior studies were limited by modest sample sizes and/ or a retrospective study design. Thus, to examine the association between statin use and survival among patients with pancreatic adenocarcinoma, we conducted a prospective study within 2 large US cohorts that ascertained detailed information on prediagnosis statin use over an extended period of follow-up evaluation. Prospectively collected, nationwide data allowed us to examine prediagnosis statin use and survival in a representative sample of pancreatic cancer patients in the United States, to explore the temporal prognostic association of prediagnosis statin use without substantial recall bias, and to adjust for a comprehensive set of lifestyle factors.
Methods

Study Population
We collected data from 2 ongoing prospective US cohort studies, the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). The NHS enrolled 121,700 female nurses aged 30 to 55 years in 1976. 17 The HPFS enrolled 51,529 male health professionals aged 40 to 75 years in 1986. 18 Participants from both cohorts completed mailed questionnaires that collected information on demographics, lifestyle habits, medical history, medication use, and health outcomes, including cancer diagnoses.
We included 648 patients diagnosed with incident pancreatic cancer between 2000 and 2013 and followed up with them through May 31, 2014 (NHS), or January 31, 2014 (HPFS). Follow-up questionnaires were completed every 2 years, with follow-up rates exceeding 90%. 19 We excluded patients with nonadenocarcinoma histology or a history of cancer at baseline (except nonmelanoma skin cancer), and patients without available data on prediagnosis statin use and survival.
Informed consent was obtained from all participants in each cohort, and the studies were approved by the Human Research Committee at Brigham and Women's Hospital (Boston, MA).
Ascertainment of Statin Use
Information on statin use was first assessed by the 2000 questionnaire and updated biennially. In 2000, participants were asked whether they used statins regularly (yes/no), as well as the duration of statin use (0-2, 3-5, or !6 y in NHS; and 1-2, 3-5, 6-9, or !10 y in HPFS). The duration of statin use was calculated from participant responses from the 2000 questionnaire combined with subsequent current use responses on follow-up questionnaires. Details on statin use ascertainment in these cohorts have been described previously. 20, 21 The primary exposure for the current study was prediagnosis statin use as reported on the questionnaire before the pancreatic cancer diagnosis.
Ascertainment of Covariates
Data on covariates were collected at baseline (in 1980 for NHS, in 1986 for HPFS) and on follow-up questionnaires including age, sex, race/ethnicity, smoking status, body mass index (BMI), and diabetes mellitus (DM) status. Information on the use of aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), and angiotensin system inhibitors also was collected (detailed in the Supplementary Methods).
22-24
Ascertainment of Pancreatic Cancer Cases
Patients with pancreatic cancer were identified by self-report, next of kin, or review of the computerized National Death Index. Physicians blinded to exposure status confirmed the diagnosis of pancreatic cancer by review of medical records, death certificates, or cancer registry data. Deaths were ascertained from next of kin, US postal service, or the National Death Index; this method has been shown to capture more than 98% of deaths. 25 The date of pancreatic cancer diagnosis and stage at diagnosis were determined through physician review of medical records. Cancer stage was classified as follows: localized (amenable to surgical resection), locally advanced (unresectable owing to extrapancreatic extension but no distant metastases), or metastatic.
Statistical Analysis
We examined the association between prediagnosis statin use (regular vs nonregular use) and overall survival among patients with pancreatic cancer. Overall survival time was calculated as the time from pancreatic cancer diagnosis to death or last follow-up evaluation, whichever came first. We used Cox proportional hazards regression models to calculate hazard ratios (HRs) and 95% CIs for overall mortality by prediagnosis statin use. The multivariable Cox regression models were adjusted for age at diagnosis (continuous), cohort (sex), race/ ethnicity (white, black, other, or unknown), year of cancer diagnosis (2000-2005 or 2006-2013) , smoking status (never, past, current, or unknown), BMI (continuous), and DM status (no, recent onset [ 4 y before cancer diagnosis], or long-standing [>4 y before cancer diagnosis]). Further adjustments were made for cancer stage at diagnosis (localized, locally advanced, metastatic, or unknown), a covariate not included in the initial model because it may be part of the causal pathway between prediagnosis statin use and pancreatic cancer survival. Given that medications frequently prescribed with statins also may have antitumor effects on pancreatic cancer, [26] [27] [28] we further examined prediagnosis use (regular vs nonregular use) of aspirin, other NSAIDs, and angiotensin system inhibitors as confounders in our analyses of statin use and patient survival.
The assumption of proportionality of hazards was satisfied by evaluating a time-dependent covariate, which was the cross-product of prediagnosis statin use and survival time (P ¼ .48). We estimated the median overall survival time and survival curves adjusted for covariates by using direct adjusted survival estimation. 29, 30 This method uses the Cox regression model to estimate survival probabilities at each time point for each individual and averages them to obtain an overall survival estimate. We examined the heterogeneity in the association of prediagnosis statin use with pancreatic cancer survival between the cohorts using the Cochran Q statistic. 31 We computed a pooled HR for overall mortality by prediagnosis statin use using the DerSimonian and Laird 32 random-effects model. As exploratory analyses, we assessed reported statin use by 2-year time intervals before pancreatic cancer diagnosis and examined whether the association of prediagnosis statin use with pancreatic cancer survival differed by lag time between statin use and cancer diagnosis. We also performed stratified analyses by year of diagnosis, smoking status, BMI, DM status, and cancer stage at diagnosis. We assessed statistical interaction by entering main effect terms and the cross-product of prediagnosis statin use and a stratification variable into the model and evaluating likelihood ratio tests.
Two-sided P values less than .05 were considered statistically significant. All statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute, Cary, NC).
Results
Characteristics of 648 patients diagnosed with incident pancreatic adenocarcinoma over the follow-up period are summarized by cohort and prediagnosis statin use in Table 1 and Supplementary Table 1, respectively. In the combined population, 247 patients (38.1%) were regular statin users before the diagnosis of pancreatic cancer. The median adjusted survival time by stage was 18, 9, and 3 months for localized, locally advanced, and metastatic disease, respectively. At the end of the follow-up period, 633 pancreatic cancer cases (97.7% of the combined cohort) were deceased.
Compared with patients who did not regularly take statins before the diagnosis of pancreatic cancer, regular statin use was associated with longer survival after adjustment for age, cohort (sex), race/ethnicity, year of diagnosis, smoking status, BMI, and DM status within the combined population (HR, 0.82; 95% CI, 0.69-0.97; P ¼ .02) ( Table 2 and Figure 1 ). The absolute difference in survival was modest, with median adjusted survival times of 6 months for regular statin users compared with 5 months for nonregular statin users. In the multivariable model further adjusted for cancer stage, the association of regular statin use before diagnosis with longer survival was similarly observed (HR, 0.83; 95% CI, 0.70-0.99; P ¼ .03) ( Table 2) . When further adjusted for prediagnosis use of aspirin, other NSAIDs, and angiotensin system inhibitors in the Cox regression model, we observed a consistent association of prediagnosis statin use and survival among patients with pancreatic cancer (HR, 0.83; 95% CI, 0.70-0.99). In addition, we did not observe synergistic effects of statins and any of these medications (data not shown). Notably, patients who regularly used statins before their diagnosis had a greater likelihood of presenting with localized disease compared with nonusers, but this did not reach statistical significance (Supplementary Table 2 ). Figure 2 shows cohort-specific results for overall survival in pancreatic cancer cases by prediagnosis statin use. Although we did not observe statistically significant heterogeneity in the association of prediagnosis statin use with survival by cohort (P ¼ .65), the association with survival was nominally stronger in NHS cases compared with HPFS cases.
To examine the temporal association of prediagnosis statin use with pancreatic cancer survival, we evaluated statin use reported in each 2-year time interval before cancer diagnosis and found that the prognostic association of regular statin use appeared to be strongest with use within 2 years of cancer diagnosis, as opposed to earlier time periods (Table 3) .
We observed no statistically significant effect modification for the prognostic association of prediagnosis statin use by year of diagnosis, smoking status, BMI, or DM status (Table 4 ). In addition, we did not observe a statistically significant interaction between prediagnosis statin use and cancer stage in relation to pancreatic cancer survival (P interaction ¼ .54) ( Table 4 and Supplementary Figure 1) . 
Discussion
To test the hypothesis that prediagnosis statin use is associated with improved clinical outcomes in patients with pancreatic adenocarcinoma, we conducted a large prospective study that included more than 600 patients with pancreatic cancer and detailed information on prediagnosis statin use. Compared with nonregular statin users before their diagnosis of pancreatic cancer, we found an approximate 20% reduction in the hazards for overall mortality among regular statin users. Although studies have suggested that regular use of aspirin or angiotensin system inhibitors may reduce the incidence and mortality of pancreatic cancer, [26] [27] [28] prediagnosis statin use appeared to associate with longer patient survival independent of these medications.
In line with previous retrospective analyses, [12] [13] [14] [15] [16] 33, 34 our large prospective study identified improved survival among patients with pancreatic cancer who regularly used statins. Interestingly, in a recent study of 2142 US patients with pancreatic adenocarcinoma, any statin use (before or after diagnosis) was associated with improved overall survival compared with nonstatin use (HR, 0.87; 95% CI, 0.79-0.97), independent of cholesterol levels. 12 This study supports a potential lipid-independent mechanism by which statins may impact mortality in pancreatic cancer. Nevertheless, a small randomized trial of statin use with chemotherapy has been performed in patients with advanced pancreatic cancer. In this trial of 114 patients with unresectable pancreatic cancer, simvastatin failed to show a survival benefit when added to single-agent gemcitabine. 35 However, a low dose of simvastatin was administered, and multi-agent chemotherapy programs have become the standard of care for advanced pancreatic cancer, rather than single-agent gemcitabine. 36 Statins inhibit the conversion of 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, which suppresses intracellular cholesterol synthesis, thereby reducing intermediate isoprenoids that serve as posttranslational regulators of proteins involving the cell cycle and proliferation. 6, 37 The downstream proteins that are potentially suppressed by statins include RAS and the Rho family of proteins, which are strongly implicated in carcinogenesis. 7, 11 Along with inhibition of multiple signaling pathways involved in cell growth (RAF/mitogenactivated protein kinases and phosphatidylinositol-4, 5-bisphosphate 3-kinase/AKT/mechanistic target of rapamycin kinase pathways), 8, 38 statins also may suppress cell proliferation and angiogenesis as well as induce apoptosis in cancer cells. 5, 6, 8 In mouse models of pancreatic cancer, simvastatin and atorvastatin suppressed the formation and progression of pancreatic neoplasms, 39 potentially through down-regulation of the RAS protein. 40 Evidence also points to immunomodulatory effects of statins as an alternative mechanism for cancer suppression because statins may enhance the reactivity of immune cells in the tumor microenvironment. 7, 8 Notably, statin use reported within the 2 years of pancreatic cancer diagnosis was associated most strongly with patient survival. Given studies suggesting no chemopreventative effects of statins on the incidence of pancreatic cancer, [41] [42] [43] statins may exert greater antitumor properties at a later phase of tumor development or after clinical manifestation. Further studies are warranted to investigate temporal changes in suppressive effects of statins on neoplastic cells during the evolution of pancreatic adenocarcinoma.
Limitations of the current study should be considered. We did not analyze data on the specific statin medication used, postdiagnosis statin use, or the dosage and frequency beyond the patient's report of regular use. Our cohort studies collect limited data on cancer treatments, and chemotherapy regimens for our patients were not known. Nonetheless, statin use is unlikely to be associated with choice of treatment program, and chemotherapy options available during the study were limited primarily to 5-fluorouracil/folinic acid or gemcitabine. In addition, our findings remained consistent after adjustment for cancer stage and year of diagnosis by which treatment strategies were largely determined. We used overall mortality as the primary study end point rather than pancreatic cancer-specific mortality. However, pancreatic cancer is a highly lethal malignancy, 1 and the majority of patients die from this disease, such that overall mortality is considered a reasonable surrogate for clinical outcomes in pancreatic cancer. Although we cannot rule out the possibility of unmeasured confounding, our multivariable models included multiple known and potential variables associated with pancreatic cancer survival, and this adjustment did not significantly alter our results. If patients regularly taking statins received closer medical attention, then it is possible that the diagnosis was made earlier with the potential for more aggressive therapy and longer survival. Finally, our study participants were predominately white populations. Therefore, further investigation on the influence of prediagnosis statin use on pancreatic cancer survival in more racially diverse populations is warranted.
Our study also has several notable strengths, including a prospective study design and large sample size with more than 600 pancreatic cancer cases. Importantly, our study population consisted of patients with all stages of pancreatic cancer diagnosed in hospitals throughout the United States, increasing the generalizability of our findings. Notably, survival times for patients in the current study were highly similar to those reported in the National Cancer Database, 44 suggesting that our cohort acts as a reasonable approximation of the general population of pancreatic cancer patients in the United States. Prospectively collected data allowed us to examine the long-term effects of prediagnosis statin use on patient survival without substantial recall bias, to rigorously adjust for potential confounders, and to evaluate for effect modification by other prognostic factors.
In conclusion, regular statin use before diagnosis was associated with improved survival among patients with pancreatic adenocarcinoma in 2 large US cohorts followed up prospectively over more than 10 years of follow-up evaluation. Given the overall low rates of serious adverse events with statin use 11 and plausible biological mechanisms for their antitumor properties, statin use should be considered for further study in pancreatic cancer.
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